Reports Q3 revenue $15.2B, consensus $15.36B. Pascal Soriot, Chief Executive Officer, AstraZeneca (AZN), commenting on the results said: “The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition. Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results including high-impact readouts for baxdrostat in hypertension and Enhertu and Datroway in breast cancer. We are also delivering on our strategy to strengthen our operations in the United States to power our growth. This includes a historic agreement with the US government to lower the cost of medicines for American patients, and broadening our US manufacturing footprint having broken ground at our new $4.5bn Virginia manufacturing facility in October.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- These Are the Stocks Reporting Earnings Today – November 6, 2025
- AZN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- AstraZeneca (AZN) Wins Vote to List Directly in New York — Here’s What It Means for Investors
- AstraZeneca’s AZD6234 Study: Key Insights for Investors
- AstraZeneca holders approve listing in London, NYC and Stockholm